The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,421,486 in first-year total cost, median $224,737.
Most frequent study sections
- Special Emphasis Panel[ZDA1 GXM-A (06)]5
Most frequent institutions
- ELYSIUM THERAPEUTICS, INC.2
- ACURA PHARMACEUTICALS, INC.1
- COLLEGIUM PHARMACEUTICAL, INC.1
- PLUMB PHARMACEUTICALS, INC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Development of Oxymorphone DETERx, an abuse-deterrent, extended-release opioid fo1R44DA037956-01 | KOPECKY, ERNEST A | COLLEGIUM PHARMACEUTICAL, INC., MA | $472,811 | ZDA1 |
| 2014 | A proposal to develop a self-regulating hydromorphone tablet to deter excess oral1R44DA037921-01 | BRZECZKO, ALBERT W | ACURA PHARMACEUTICALS, INC., IL | $299,694 | ZDA1 |
| 2014 | Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs1R44DA037908-01 | JENKINS, THOMAS E | ELYSIUM THERAPEUTICS, INC., CO | $224,737 | ZDA1 |
| 2014 | Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance1R44DA037900-01 | JENKINS, THOMAS E | ELYSIUM THERAPEUTICS, INC., CO | $217,526 | ZDA1 |
| 2014 | Long acting injected liposomal buprenorphine for chronic pain/addiction in people1R43DA037887-01 | HEATH, TIMOTHY DKRUGNER-HIGBY, LISA ANN | PLUMB PHARMACEUTICALS, INC, WI | $206,718 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.